Adaptimmune Therapeutics plc (ADAP) NASDAQ

0.08

-0.0004(-0.50%)

Updated at August 01 04:00PM

Currency In USD

Adaptimmune Therapeutics plc

Address

60 Jubilee Avenue

Abingdon, OX14 4RX

United Kingdom of Great Britain and Northern Ireland

Phone

44 12 3543 0000

Sector

Healthcare

Industry

Biotechnology

Employees

506

First IPO Date

May 06, 2015

Key Executives

NameTitlePayYear Born
Mr. Adrian G. RawcliffeChief Executive Officer & Director1.04M1972
Ms. Cintia Piccina Pharm.D.Chief Commercial Officer510,5091973
Mr. John LungerChief Patient Supply Officer645,9081969
Dr. Elliot Norry B.A., M.D.Chief Medical Officer676,1941963
Dr. Helen Katrina Tayton-Martin MBA, Ph.D.Co-Founder677,4041967
Mr. William C. A. Bertrand Jr., Esq., J.D.Chief Operating Officer & Chief Compliance Officer703,0971965
Dr. Juli P. Miller Ph.D.Vice President of Corporate Affairs & Investor Relations0N/A
Ms. Joanna Brewer Ph.D.Chief Scientific Officer01976
Ms. Dana LynchSenior Director of Corporate Communications0N/A
Ms. Kerry SharpSenior Vice President & General Counsel0N/A

Description

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.